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The pH (low) insertion peptide (pHLIP) family enables targeting of
cells in tissues with low extracellular pH. Here, we show that
ischemic myocardium is targeted, potentially opening a new route
to diagnosis and therapy. The experiments were performed using
two murine ischemia models: regional ischemia induced by coro-
nary artery occlusion and global low-flow ischemia in isolated
hearts. In both models, pH-sensitive pHLIPs [wild type (WT) and
Var7] or WT-pHLIP–coated liposomes bind ischemic but not normal
regions of myocardium, whereas pH-insensitive, kVar7, and lipo-
somes coated with PEG showed no preference. pHLIP did not in-
fluence either the mechanical or the electrical activity of ischemic
myocardium. In contrast to other known targeting strategies, the
pHLIP-based binding does not require severe myocardial damage.
Thus, pHLIP could be used for delivery of pharmaceutical agents or
imaging probes to the myocardial regions undergoing brief restric-
tions of blood supply that do not induce irreversible changes
in myocytes.
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The pH (low) insertion peptide (pHLIP) enables targeting ofcells in tissues with low extracellular pH (1). In this publi-
cation, we show that ischemic myocardial tissues are targeted,
potentially opening new avenues for diagnosis and therapy. The
pHLIP family consists of water-soluble polypeptides originally
derived from the bacteriorhodopsin C helix, which is triggered by
low pH to insert and fold across a membrane to form a stable
transmembrane α helix as a consequence of titrating two carboxyl
groups in the transmembrane (TM) helix to render them un-
charged (2). In solution, at pH values above 7.0–7.2, a typical
pHLIP partitions as a mainly unstructured peptide to the surface
of a lipid bilayer, inserting when the pH drops from neutral or
high to slightly acidic (7.0–6.5 and less). The insertion process is
unidirectional and rapid (<2 min in lipid vesicles) (3–5). Varia-
tions of the pHLIP sequence can be used to change the time
required for insertion across and exit from the membrane,
ranging from milliseconds to minutes (6). The apparent pK of
insertion across a liposomal bilayer membrane is 6.0 for the
original WT-pHLIP sequence (2). pHLIP has been shown to
locate imaging agents in tumors and arthritic inflammation (7–
11), and to accomplish pH-selective cytoplasmic delivery of
peptide nucleic acids, fluorescent dyes, and anticancer agents (3,
12, 13). Low pH is associated with a number of important path-
ological states including myocardial ischemia. According to the
American Heart Association (14), ∼9 million Americans are
estimated to experience angina pectoris, and a similar incidence
of angina has been estimated for most European countries (15).
It has been demonstrated that extracellular pH is lowered in
ischemic heart models (16, 17) and clinically in patients during
pacing-induced ischemia in coronary artery disease (18). To
follow targeting by pHLIP, fluorescent dyes and fluorescently
labeled liposomes coated with pHLIP were used as imaging
agents. Experiments were carried out using two murine models
of myocardial ischemia: regional ischemia induced by coronary
artery occlusion in situ and low-flow ischemia in isolated perfused
hearts. In this paper, we demonstrate that either pHLIP peptides
or pHLIP-coated liposomes selectively accumulate in ischemic
myocardium.
Results
Local Myocardial Ischemia in Situ. We used three forms of pHLIP
to study whether pHLIP peptides accumulate selectively in is-
chemic myocardium in the area at risk: WT, a slow inserting
form; Var7, a fast inserting form with E substitutions for the two
D positions in the TM helix; and kVar7, a noninserting form with
K substitutions for the TM D positions. pHLIP variants were
injected 3 min before arterial occlusion, and no acute changes of
electrocardiogram (ECG) parameters were seen from the in-
jection (SI Data, Table S1). Subsequent occlusion of the left
coronary artery induced tissue discoloration and an elevation of
the S-T segment of the ECG that is typical of myocardial is-
chemia within several seconds (Fig. 1A). The size of the area at
risk expressed as a percentage of left ventricular volume did not
differ among the experimental groups: 46 ± 4%, 45 ± 7%, 40 ±
6%, and 43 ± 4% (number of samples; n = 5, 5, 5, and 4 for
saline, kVar7, WT, and Var7, respectively).
The main purpose of the experiments with local ischemia was
to test whether pHLIP accumulates selectively in ischemic myo-
cardium in the area at risk. This was done by comparing the
mean fluorescence intensity of Alexa 488-pHLIPs in the area at
risk with the normal myocardium. The contrast of fluorescence
was higher in the hearts from the mice injected with pH-sensitive
WT and Var7, compared with the pH-insensitive kVar7, and was
maximal in the group injected with Var7 (Fig. 1 B–D and H). We
also compared the mean intensity of fluorescence of Alexa 488-
Var7 in the areas at risk in the mice subjected to ischemia and in
the sham-operated mice not subjected to ischemia. The mean
intensity of fluorescence was significantly higher in the hearts
subjected to local ischemia than in the sham group with no is-
chemia [54 ± 7 vs. 13 ± 4 arbitrary units (A.U.); n = 4 and 5; P <
0.05]. Anatomically, the region of relatively bright fluorescence
in the presence of pH-sensitive pHLIPs coincides with the area
at risk (Fig. 1 F and G). These findings suggest that pH-sensitive
WT and Var7 selectively target ischemic myocardium, but not
the pH-insensitive kVar7 pHLIP.
Low-Flow Myocardial Ischemia in Isolated Hearts. In another ap-
proach, we evaluated the ability of the pH peptides to selectively
target the ischemic myocardium using a model of low-flow global
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ischemia in isolated hearts, where better control of coronary flow
can be achieved. As shown by the increased mean intensity of
fluorescence, the Alexa 488-Var7 was present in significantly
higher amounts in the ventricles of the hearts subjected to low-flow
global ischemia than in the normally perfused heart controls (Fig.
2 A, C, and D). These results are consistent with the observation
that Var7 is selectively bound to ischemic myocardium in situ.
To test whether pH sensitivity is important for pHLIP binding
to ischemic myocardium, we used the pH-insensitive kVar7 and
found that the mean intensity of fluorescence for pH-insensitive
Alexa 488-kVar7 was significantly less than for the pH-sensitive
Alexa 488-Var7. In the normally perfused hearts, however,
binding of labeled kVar7 does not differ from Alexa 488-Var7
(Fig. 2 B and D), supporting the idea that pH sensitivity is the
key for selective binding of pHLIP to ischemic myocardium.
Using the model of low-flow myocardial ischemia in isolated
hearts, we also tested the ability of WT-pHLIP–coated liposomes
to target ischemic myocardium. Significantly higher values of the
mean intensity of fluorescence reveal more WT-pHLIP lipo-
somes in the ventricular myocardium of the hearts subjected to
ischemia than in the normally perfused hearts (Fig. 2 E, G, and
H). Control liposomes coated with carboxyl-terminated PEG
(designed to have the same density of negative charges on the
liposome surface as in the case of the pHLIP coating) did not
accumulate in ischemic myocardium (Fig. 2 F and H), showing
that the presence of pHLIP is the agent for targeting.
Histological examination revealed that the pattern of staining
with Alexa 488-WT-pHLIP and WT-pHLIP–coated liposomes is
different (Fig. 3). Alexa 488-WT-pHLIP stained plasma mem-
branes (Fig. 3A), as had been shown previously in tumor models
Fig. 1. Experiments with local myocardial ischemia in situ. (A) Example of lead II ECG recordings at baseline (Upper) and at 30 s of occlusion (Lower) showing
typical elevation of ST segment induced by left coronary artery occlusion. (B–E) Typical fluorescence images of sections from the hearts of four mice subjected
to different experimental interventions: (B) sham procedure (instead of ischemia induction) with injection of pH-sensitive WT-pHLIP; (C) ischemia, pH-in-
sensitive kVar7; (D) ischemia, pH-sensitive WT; and (E) ischemia, pH-sensitive Var7. LV, left ventricle; RV, right ventricle; Sept, septum. (F and G) Area at risk
delineated with Evans Blue (light yellow in white-light image F) coinciding with area of bright fluorescence (fluorescence image G) in a section of the heart
from a mouse injected with Var7. (H) Contrast of fluorescence in the area at risk vs. intact myocardium. Mean ± SEM values are shown; n = 5, 5, 5, 4 for no
ischemia, kVar7, WT, and Var7, respectively. *P < 0.05 vs. no ischemia or kVar7; +P < 0.05 vs. WT.
Fig. 2. Experiments with low-flow ischemia in isolated mouse hearts. (A–C) Alexa 488 fluorescence images of sections from three isolated mouse hearts: (A)
not subjected to low-flow ischemia and perfused with pH-sensitive Var7; (B) subjected to low-flow ischemia and perfused with pH-insensitive kVar7; and (C)
subjected to low-flow ischemia and perfused with pH-sensitive Var7. (D) Summary data for mean intensity of fluorescence (in arbitrary units). Mean ± SEM
values are shown; n = 5 for all groups. *P < 0.05 vs. Var7 minus ischemia and kVar7 plus ischemia. (E–G) Rhodamine fluorescence images of sections from three
isolated mouse hearts: (A) not subjected to low-flow ischemia and perfused with liposomes coated with pH-sensitive WT; (B) subjected to low-flow ischemia
and perfused with liposomes coated with PEG; and (C) subjected to low-flow ischemia and perfused with liposomes coated with pH-sensitive WT. (G)
Summary data for mean intensity of fluorescence. Mean ± SEM values are shown; n = 5, 4, and 5 for WT minus ischemia, PEG plus ischemia, and WT plus
ischemia, respectively. *P < 0.05 vs. WT minus ischemia or PEG plus ischemia.

















in vivo (9), whereas rhodamine-labeled lipids from the targeted
liposomes appear to have reached intracellular organelles like
mitochondria (Fig. 3B).
Isolated Left Atrial Appendages. We began experiments with iso-
lated atrial appendages by examining the effect of pH on pHLIP
binding to the myocardial tissues. With the pH-sensitive Alexa
488-Var7, accumulation of pHLIP (assessed by the mean in-
tensity of fluorescence) was significantly higher when the pH was
6.5 compared with 7.4 (Fig. 4 A, D, and E). An equally bright
fluorescence at low pH 6.5 was found with the pH-sensitive
Alexa 488-WT (Fig. 4 C and E) but not with the pH-insensitive
Alexa 488-kVar7 (Fig. 4 B and E). Thus, pH-sensitive pHLIP
variants accumulate in the atrial myocardium to a greater extent
at lower pH than at higher pH.
The main goal of this series of experiments was to assess the
effects of the pH-sensitive Alexa 488-Var7 pHLIP on the elec-
trical and mechanical activity of paced left atrial appendages in
the normal and low pH environment. At pH 7.4, Var7 had no
effect either on the force developed or on parameters of trans-
membrane potential (Fig. 5 A and B; Table S2). The decrease in
pH by itself caused a significant reduction of the force developed
without any significant change in the parameters of trans-
membrane potential (Fig. 5 C and D; Table S2). Administration
of Var7 at low pH had no additional effect on the force de-
veloped or on the transmembrane potential (Fig. 5 D and E; SI
Data, Table S2). Thus, exposure to the pH-sensitive Var7-pHLIP
did not significantly influence the mechanical or electrical ac-
tivity in preparations of left atrial appendages of mice.
Discussion
During the past few years, several techniques for passive and
active imaging and drug delivery in diseased cardiac tissue have
been developed (19, 20), including various types of nanoparticles
for drug delivery such as liposomes, drug–polymer conjugates,
polymeric micelles, dendrimers, nanoshells, and nucleic acid-
based carriers (21). Passive drug delivery is based on the fact
that the endothelial lining of the blood vessel wall becomes
more permeable in infarcted areas so that large molecules and
even relatively large nanoparticles (micelles and liposomes) can
leave the vascular bed and accumulate inside the infarcted re-
gion (22–24). For active targeting, monoclonal antibodies against
characteristic components of ischemic myocardium are the most
frequently used vector molecules. Cellular components that are
normally localized intracellularly but exposed extracellularly due
to membrane disruptions in necrotic myocytes (e.g., intracellular
cardiac myosin, phosphatidylserine, cytoskeleton) are used as
biomarkers (19, 24–27). P-selectin expression, which reaches
a peak of up-regulation at 4 h after myocardial infarction, has
also been used as a biomarker (28). Analysis of the existing
methods for selective drug delivery in diseased cardiac tissue
shows that these techniques have a general distinctive feature:
they need severe myocardial ischemia or infarction (leaky vas-
culature for passive delivery or cell apoptosis for active targeting)
and are therefore useful only in tissue repair or regenerative
strategies.
In contrast, we find in this study that pH-sensitive WT and
Var7-pHLIPs and WT-pHLIP–coated liposomes selectively tar-
get ischemic myocardium in tissues that are less damaged than is
required for the targeting strategies previously used. The results
were obtained in two murine ischemia models: regional ischemia
induced by coronary artery occlusion and global low-flow ische-
mia in isolated hearts. Also, we find that the controls, pH-in-
sensitive kVar7 and liposomes coated with PEG, do not target
the ischemic myocardium in our models. The selective binding of
pH-sensitive pHLIPs in ischemic myocardium is consistent with
the original concept of targeting of acidic tumors (5, 8, 9, 29),
while it is not a trivial consequence thereof. Importantly, accu-
mulation of pHLIP in ischemic myocardium did not influence its
mechanical or electrical activity. This result is in accordance with
our previous data showing that the interaction of pHLIP with
cellular membranes at both neutral and low pH does not lead to
membrane leakage (4, 30) or cellular toxicity (7) over a range of
peptide concentrations. A distinctive feature of pHLIP-based
targeting of ischemic myocardium is that pHLIP binding does
not require severe myocardial damage and should work in the
myocardial region undergoing brief restrictions of blood supply
that do not induce irreversible changes in cardiomyocytes. Such
Fig. 3. Confocal images showing details of staining of two isolated hearts
subjected to low-flow ischemia and perfused either with Alexa 488-WT-
pHLIP (green; A) or with liposomes containing Rho-lipids and coated with
WT-pHLIP (red; B). DAPI-stained nuclei are blue.
Fig. 4. (A–D) Fluorescence images of four mouse left atria exposed to (A) Var7 at the normal pH, (B) kVar7 at pH 6.5, (C) WT at pH 6.5, and (D) Var7 at pH 6.5.
(E) Summary data for mean intensity of fluorescence (in arbitrary units). Mean ± SEM values are shown; n = 5 for all groups. *P < 0.05 vs. Var7 at pH 7.4 or
kVar7 at pH 6.5.
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a brief restriction of blood supply is typical for angina pectoris.
The major problem with medical treatment for angina is that all
antianginal drugs have cardiac and noncardiac side effects that
significantly restrict their utilization (15). Most of the adverse
effects result from the fact that the antianginal drugs affect tis-
sues and organs throughout the body. The results of the present
study suggest that pHLIP might be used as a carrier for de-
livering pharmaceutical agents specifically into ischemic regions
during anginal attacks. Although there are no direct measure-
ments of intracellular or extracellular pH in ischemic areas
during angina attacks in humans, there is evidence that pH drops
to values low enough to allow pHLIP binding to ischemic myo-
cardium: a range of pH values can be estimated indirectly using
the fact that angina episodes are sensed as a chest pain, which
results from the activation of cardiac sensory neurons by acidosis
(31). It has been shown that chest pain caused by myocardial
ischemia is mediated by cardiac sympathetic (C-fiber) afferents
(32). Specifically, the acid-sensing ion channel 3 (ASIC3), which
is expressed at extremely high levels in sensory neurons in-
nervating the heart, functions as a pH sensor (33, 34). The ac-
tivation threshold for the channel is about 7.0 and the half-
activation value is between 6.7 and 6.6 (33–36). Thus, sensing
chest pain during angina episode implies pH values within the
pHLIP insertion range, which allows us to hypothesize that
pHLIP can effectively bind and accumulate in the region of re-
stricted blood flow. Because a decrease in pH occurs very rapidly
(within a few minutes) after the onset of ischemia, we suggest
that pHLIP might quickly deliver antianginal agents to ischemic
regions, decrease the oxygen supply/demand ratio and therefore
cell damage, and manage the anginal attack avoiding the mul-
tiple side effects of antianginal drugs. Because pHLIP can de-
liver polar cell-impermeable molecules intracellularly, a number
of new therapeutic compounds might be formulated. Moreover,
pHLIP-coated liposomes might be used to deliver a mixture of
pharmaceuticals to the risk zone. Thus, we assume that pHLIP
technology might have a significant impact on the treatment of
chronic angina.
pHLIP could deliver therapeutic agents, imaging agents, or
both at the same time, acting as a theranostic. The most
straightforward cardiac application of pHLIP could be for im-
aging ischemic regions in myocardium, and might be especially
important for the diagnosis of myocardial ischemia in pediatric
patients. The problem with current tests is that the ST-segment
elevation in ECG used as a sign of myocardial ischemia in adults is
often misleading in the young (37), whereas radiography may re-
veal significant anatomical abnormalities conducive to myocardial
ischemia but not myocardial ischemia per se. Obviously, it would
be advantageous to have an agent visualizing ischemic myocar-
dium at the stage of basic X-ray examination of children. To
diagnose myocardial ischemia in children, exercise or pharma-
cologic cardiac stress is induced. We expect that pHLIP will
target the acidic myocardium during the acute ischemia associ-
ated with cardiac stress and deliver contrast agents to any is-
chemic region, opening new opportunities in use of existing
imaging modalities for the diagnosis of myocardial ischemia
in children.
In conclusion, the results of our study demonstrate that
pHLIPs or pHLIP-coated liposomes target ischemic but not
normal regions of myocardium. pHLIP accumulation does not
influence either the mechanical or the electrical activity of is-
chemic myocardium. Importantly, pHLIP recognizes ischemic
tissue due to a drop in extracellular pH. Therefore, pHLIP can
deliver pharmaceutical agents or imaging probes to the myo-
cardial region undergoing brief restrictions of blood supply,
which do not induce irreversible changes in myocytes. This is an
important advantage that distinguishes pHLIP-based technolo-
gies from other existing methods of ischemic myocardium
targeting.
Materials and Methods
The investigation conforms to the Guide for the Care and Use of Laboratory
Animals published by the National Institutes of Health (38) and the rules of
the Columbia University Institutional Animal Care and Use Committee. The
experimental techniques were generally similar to those described by us
previously (39, 40).
Constructs Used in Study. The goal of our study was to evaluate ability of
fluorescently labeled pHLIPs and pHLIP-coated liposomes to target ischemic
myocardium. Several pHLIP variants were used in the study as follows: WT,
ACEQNPIY WARYADWLFTTPLLLLDLALLV DADEGT; Var7, ACEEQNP WAR-
YLEWLFPTETLLLEL; and kVar7, ACEEQNP WARYLKWLFPTKTLLLKL (under-
lining indicates transmembrane domain in peptides).
WT is a well-characterized pHLIP peptide that targets acidic tissue by virtue
of the titration and neutralization of the carboxyl groups in the TM region.
Var7 is a recently introduced truncated version of WT, which has a higher pK
of insertion (substituting Glu for Asp in the TM) and much faster blood
clearance. It was designed for PET/single-photon emission computed to-
mography imaging. kVar7 is a pH-insensitive peptide that does not target
acidic tissue, because the protonatable Glu residues are replaced by posi-
tively charged Lys residues. Each peptide was conjugated with the Alexa 488
fluorescent dye. Additionally, we tested WT-pHLIP–coated and PEG-coated
liposomes containing fluorescent rhodamine-PE lipids. The following lipo-
some formulations (mol %) were investigated for targeting of ischemic
myocardium: WT-pHLIP–coated liposomes: 90% DOPC, 5% Rho-PE, 5%
pHLIP-PE; and PEG-coated liposomes: 90% DOPC, 5% Rho-PE, 5% DSPE-
PEG2000-COOH.
The experimentswith pHLIP peptides and liposomeswere carried out using
two murine ischemia models: regional ischemia induced by coronary artery
occlusion and global low-flow ischemia in isolated hearts.
Preparation of Constructs. pHLIP peptides were prepared by large-scale solid-
phase peptide synthesis using 9-fluorenylmethyloxycarbonyl (Fmoc) chem-
istry at the W. M. Keck Foundation Biotechnology Resource Laboratory at
Yale by James Elliott (Yale University, New Haven, CT). The detailed de-
scription of peptide conjugations with fluorescent dyes and lipids can be
found in SI Data. Liposomes of two different compositions coated with
pHLIP (5 mol % pHLIP-PE, 5% Rho PE, 90% DOPC) and control liposomes
coated with PEG (5% DSPE-PEG2000-COOH, 5% Rho-PE, 90% DOPC) were
prepared by extrusion; the details are presented in SI Data.
Local Myocardial Ischemia in Situ. Male C57B mice weighing 23–32 g were
anesthetized with sodium pentobarbital (50–70 mg/kg, i.p.; added per need
in the course of experiment) and artificially ventilated at a rate of 120 pulse/
min with a tidal volume of 0.5 mL (Harvard Apparatus Respirator; model
Fig. 5. Typical recordings showing the absence of Var7 effects on trans-
membrane potential and contractile activity in the left atrium at the normal
(A and B) and low (C–E) pH. (A and B) Recordings of developed force (top
trace), transmembrane potential (middle trace), and maximum upstroke
velocity (peak of the first derivative of transmembrane potential shown in
the bottom trace) in predrug control (A) and after 30 min in the presence of
10 μM Var7 (B) obtained from a preparation of the left atrium at pH 7.4.
(C–E) Recordings at the normal pH (C), after 20 min at pH 6.5 (D), and after
30 min in the presence of 10 μM Var7 at pH 6.5 (B) obtained from another
preparation of the left atrium. Notice a marked reduction in the developed
force induced by introduction of low pH.

















707). Mice received heparin (1,000 mg/kg, i.p.) and a snare around the left
coronary artery was periodically tightened (for 10 min) and reperfused (for
5 s) to imitate an obstructed coronary flow. Tested pHLIP variants (80 μM in
100 μL of PBS) were injected into the femoral vein 3 min before the first
occlusion. At the end of the protocol, the heart was excised with the left
coronary artery still occluded, the aorta was cannulated, and 1% Evans Blue
was injected into the aorta to delineate the area at risk. Frozen ventricles
were sectioned and fluorescent or white light images were obtained with
Nikon SMZ1000 UV dissection microscope. The contrast of fluorescence was
measured by comparison of the mean intensities of fluorescence in the area
at risk and in the intact myocardium.
Low-Flow Myocardial Ischemia in Isolated Hearts. Mouse hearts were excised
and placed into a cold (4 °C) physiologic solution of the following compo-
sition (in mmol/L): 150 NaCl, 4 KCl, 1.8 CaCl2, 1.0 MgCl2, 5.5 dextrose, and 10
Hepes equilibrated with 100% oxygen (pH 7.4) and promptly mounted for
retrograde Langendorff perfusion with the same solution at 37 °C and
constant flow rate of 4 mL/min while being continuously paced at a cycle
length of 200 ms. Global low-flow ischemia was induced by reducing per-
fusion rate to 0.2 mL/min during 15 min. pHLIP or liposomes coated with
pHLIP in concentration of 1 μM were administered during perfusion at
a slow rate. SI Data contain more details of the experimental procedures.
Isolated Preparations of Left Atrial Appendages. Preparations of left atrial
appendages were mounted epicardial surface up in a chamber perfused
with the same physiologic solution as used for experiments with isolated
Langendorff perfused heats. Preparations were paced at a cycle length of
250 ms; tension transducer and conventional microelectrode techniques
were used to register isometric developed force and transmembrane po-
tential. Effects of 30-min exposure to 10 μM pHLIP were studied at normal
and low pH (7.4 and 6.5, respectively). Further details of experimental
techniques can be found in SI Data.
Statistical Analysis. The data are presented as mean ± SEM. One- or two-way
analysis of the variance for repeated measures were used for statistical
analysis, and Bonferroni test was used for post hoc comparisons when
appropriate.
ACKNOWLEDGMENTS. This work was supported by National Institutes of
Health Grants CA133890 and GM073857 (to O.A.A., D.M.E., and Y.K.R.).
1. Andreev OA, Engelman DM, Reshetnyak YK (2010) pH-sensitive membrane peptides
(pHLIPs) as a novel class of delivery agents. Mol Membr Biol 27(7):341–352.
2. Hunt JF, Rath P, Rothschild KJ, Engelman DM (1997) Spontaneous, pH-dependent
membrane insertion of a transbilayer alpha-helix. Biochemistry 36(49):15177–15192.
3. Reshetnyak YK, Andreev OA, Lehnert U, Engelman DM (2006) Translocation of mol-
ecules into cells by pH-dependent insertion of a transmembrane helix. Proc Natl Acad
Sci USA 103(17):6460–6465.
4. Reshetnyak YK, Segala M, Andreev OA, Engelman DM (2007) A monomeric mem-
brane peptide that lives in three worlds: In solution, attached to, and inserted across
lipid bilayers. Biophys J 93(7):2363–2372.
5. Andreev OA, Reshetnyak YK (2007) Mechanism of formation of actomyosin interface.
J Mol Biol 365(3):551–554.
6. Karabadzhak AG, et al. (2012) Modulation of the pHLIP transmembrane helix in-
sertion pathway. Biophys J 102(8):1846–1855.
7. Andreev OA, et al. (2007) Mechanism and uses of a membrane peptide that targets
tumors and other acidic tissues in vivo. Proc Natl Acad Sci USA 104(19):7893–7898.
8. Vavere AL, et al. (2009) A novel technology for the imaging of acidic prostate tumors
by positron emission tomography. Cancer Res 69(10):4510–4516.
9. Reshetnyak YK, et al. (2011) Measuring tumor aggressiveness and targeting meta-
static lesions with fluorescent pHLIP. Mol Imaging Biol 13(6):1146–1156.
10. Daumar P, et al. (2012) Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide
analogues and their biological evaluation. Bioconjug Chem 23(8):1557–1566.
11. Macholl S, et al. (2012) In vivo pH imaging with (99m)Tc-pHLIP. Mol Imaging Biol
14(6):725–734.
12. An M, Wijesinghe D, Andreev OA, Reshetnyak YK, Engelman DM (2010) pH-(low)-
insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin
inhibits cancer cell proliferation. Proc Natl Acad Sci USA 107(47):20246–20250.
13. Wijesinghe D, Engelman DM, Andreev OA, Reshetnyak YK (2011) Tuning a polar
molecule for selective cytoplasmic delivery by a pH (low) insertion peptide. Bio-
chemistry 50(47):10215–10222.
14. Roger et al. (2011) Heart disease and stroke statistics—2011 update: a report from the
American Heart Association. Circulation 123(4):e18–e209.
15. Fox K, et al.; Task Force on the Management of Stable Angina Pectoris of the Euro-
pean Society of Cardiology; ESC Committee for Practice Guidelines (CPG) (2006)
Guidelines on the management of stable angina pectoris: Executive summary: The
Task Force on the Management of Stable Angina Pectoris of the European Society of
Cardiology. Eur Heart J 27(11):1341–1381.
16. Cobbe SM, Poole-Wilson PA (1980) The time of onset and severity of acidosis in
myocardial ischaemia. J Mol Cell Cardiol 12(8):745–760.
17. Hirche H, et al. (1980) Myocardial extracellular K+ and H+ increase and noradrenaline
release as possible cause of early arrhythmias following acute coronary artery oc-
clusion in pigs. J Mol Cell Cardiol 12(6):579–593.
18. Cobbe SM, Poole-Wilson PA (1982) Continuous coronary sinus and arterial pH mon-
itoring during pacing-induced ischaemia in coronary artery disease. Br Heart J 47(4):
369–374.
19. Galagudza MM, et al. (2010) Targeted drug delivery into reversibly injured myocar-
dium with silica nanoparticles: Surface functionalization, natural biodistribution, and
acute toxicity. Int J Nanomedicine 5:231–237.
20. Scott RC, Crabbe D, Krynska B, Ansari R, Kiani MF (2008) Aiming for the heart: Tar-
geted delivery of drugs to diseased cardiac tissue. Expert Opin Drug Deliv 5(4):
459–470.
21. Wang AZ, et al. (2008) Biofunctionalized targeted nanoparticles for therapeutic ap-
plications. Expert Opin Biol Ther 8(8):1063–1070.
22. Caride VJ, Zaret BL (1977) Liposome accumulation in regions of experimental myo-
cardial infarction. Science 198(4318):735–738.
23. Palmer TN, Caride VJ, Caldecourt MA, Twickler J, Abdullah V (1984) The mechanism of
liposome accumulation in infarction. Biochim Biophys Acta 797(3):363–368.
24. Torchilin VP, et al. (1992) Targeted accumulation of polyethylene glycol-coated im-
munoliposomes in infarcted rabbit myocardium. FASEB J 6(9):2716–2719.
25. Vance JE, Steenbergen R (2005) Metabolism and functions of phosphatidylserine.
Prog Lipid Res 44(4):207–234.
26. Khaw BA, DaSilva J, Hartner WC (2007) Cytoskeletal-antigen specific immunoliposome-
targeted in vivo preservation of myocardial viability. J Control Release 120(1–2):35–40.
27. Khaw BA, Torchilin VP, Vural I, Narula J (1995) Plug and seal: Prevention of hypoxic
cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat Med
1(11):1195–1198.
28. Scott RC, et al. (2007) Targeted delivery of antibody conjugated liposomal drug car-
riers to rat myocardial infarction. Biotechnol Bioeng 96(4):795–802.
29. Macholl S, et al. (2012) In vivo pH imaging with 99mTc-pHLIP. Mol Imaging Biol 14:
725–734.
30. Zoonens M, Reshetnyak YK, Engelman DM (2008) Bilayer interactions of pHLIP,
a peptide that can deliver drugs and target tumors. Biophys J 95(1):225–235.
31. Gu Q, Lee L-Y (2010) Acid-sensing ion channels and pain. Pharmaceuticals (Ott) 3(5):
1411–1425.
32. Pan HL, Longhurst JC, Eisenach JC, Chen SR (1999) Role of protons in activation of
cardiac sympathetic C-fibre afferents during ischaemia in cats. J Physiol 518(Pt 3):
857–866.
33. Benson CJ, Eckert SP, McCleskey EW (1999) Acid-evoked currents in cardiac sensory
neurons: A possible mediator of myocardial ischemic sensation. Circ Res 84(8):
921–928.
34. Sutherland SP, Benson CJ, Adelman JP, McCleskey EW (2001) Acid-sensing ion channel
3 matches the acid-gated current in cardiac ischemia-sensing neurons. Proc Natl Acad
Sci USA 98(2):711–716.
35. Yagi J, Wenk HN, Naves LA, McCleskey EW (2006) Sustained currents through ASIC3
ion channels at the modest pH changes that occur during myocardial ischemia. Circ
Res 99(5):501–509.
36. Naves LA, McCleskey EW (2005) An acid-sensing ion channel that detects ischemic
pain. Braz J Med Biol Res 38(11):1561–1569.
37. Gazit AZ, Avari JN, Balzer DT, Rhee EK (2007) Electrocardiographic diagnosis of
myocardial ischemia in children: Is a diagnostic electrocardiogram always diagnostic?
Pediatrics 120(2):440–444.
38. Committee on Care and Use of Laboratory Animals (1996) Guide for the Care and Use
of Laboratory Animals. , (Natl Inst Health, Bethesda), DHHS Publ No (NIH) 85–23.
39. Anyukhovsky EP, et al. (2011) Expression of skeletal muscle sodium channel (Nav1.4)
or connexin32 prevents reperfusion arrhythmias in murine heart. Cardiovasc Res
89(1):41–50.
40. Sosunov EA, Anyukhovsky EP, Rosen MR (2008) Altered ventricular stretch contributes
to initiation of cardiac memory. Heart Rhythm 5(1):106–113.
86 | www.pnas.org/cgi/doi/10.1073/pnas.1220038110 Sosunov et al.
